Abstracts Archive - Page 1224 of 2607 - ACR Meeting Abstracts

Abstract Number: 565 • 2018 ACR/ARHP Annual Meeting
Genetic Polymorphism in Dihydrofolate Reductase Impacts Methotrexate Polyglutamation in Adult Rheumatoid Arthritis
Thierry Dervieux¹, Marie Grosjean², Chuang Jiang^3,4, Kelley Brady¹, Kjeld Schmiegelow², Joel Kremer⁵ and Jun Yang⁴, ¹Exagen Diagnostics, Inc., Vista, CA, ²University Hospital Rigshospitalet, Copenhagen, Denmark, ³Shanghai Children’s Medical Center, Shanghai Jiaotong University School of Medicine, Shanghai, China, ⁴Department of Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, TN, ⁵Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: Methotrexate (MTX) is anti-folate activated to MTX polyglutamates (MTXPGs). MTX metabolism includes multiple enzyme-mediated reactions and genetic polymorphisms in these genes are linked to…
Abstract Number: 566 • 2018 ACR/ARHP Annual Meeting
Capillary Blood Based Methotrexate Polyglutamate Assay for Monitoring Low Dose Methotrexate Therapy in Rheumatic Diseases
Thierry Dervieux¹, Kelley Brady¹, Deborah Stimson¹, Ying Qu¹, Tyler O'Malley¹, Robert Apilado¹, Smitha Reddy², Puja Chitkara³, John Conklin¹, Roberta Alexander¹ and Claudia Ibarra¹, ¹Exagen Diagnostics, Inc., Vista, CA, ²Arthritis Care and Research Center, San Diego, CA, ³Center for Arthritis and Rheumatologic Excellence, Chula Vista, CA
Background/Purpose: The red blood cell (RBC) Methotrexate (MTX) polyglutamate (MTXPG3) assay is a helpful therapeutic drug monitoring (TDM) tool in autoimmune rheumatic diseases. Our objective…
Abstract Number: 567 • 2018 ACR/ARHP Annual Meeting
Non-Surgical Periodontal Therapy Plus Short-Term Antibiotic Treatment May Improve Clinical Disease Activity: A Pilot Study in Difficult to Treat Rheumatoid Arthritis
Burkhard Moeller¹, Philip Bender², Sigrun Eick², Kim Midwood³, Jan Potempa⁴, Stephan Reichenbach⁵, Anja Schwenzer³, Peter M. Villiger⁶ and Alicia Wong³, ¹Rheumatology, Immunology and Allergology, Inselspital, University Hospital of Bern, Bern, Switzerland, ²School of Dental Medicine, University of Bern, Bern, Switzerland, ³Kennedy Institute for Rheumatology, Oxford University, Oxford, United Kingdom, ⁴Department of Microbiology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow, Poland, ⁵Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland, ⁶University of Bern, Bern, Switzerland
Background/Purpose: Autoimmunity against citrullinated peptides is a hallmark of rheumatoid arthritis (RA). Chronic periodontitis (CP) is a known major source of citrullinated peptides. Here, we…
Abstract Number: 568 • 2018 ACR/ARHP Annual Meeting
Change in RF and Anti-CCP Isotype Levels in RA Patients Treated with Anti-TNF, Abatacept, Rituximab or Tocilizumab and Correlation with Clinical and Radiographic Outcomes: Data from a Randomized Trial
Renaud Felten¹, Marie-Alexandra Alyanakian², Lucienne Chatenoud², Jean Sibilia¹, Frédérique Gandjbakhch³, Cédric Lukas⁴ and Jacques-Eric Gottenberg¹, ¹University Hospital of Strasbourg, Department of Rheumatology, Strasbourg, France, ²Laboratoire d'Immunologie Biologique, Hôpital Necker-Enfants Malades, Paris, France, ³Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France, ⁴University Hospital Lapeyronie, Department of Rheumatology, Montpellier, France
Background/Purpose: In rheumatoid arthritis (RA), little is known about the prognostic relevance of the change in autoantibody (ab) levels. Seroconversion was reported to be associated…
Abstract Number: 569 • 2018 ACR/ARHP Annual Meeting
Clinical and Sociodemographic Characteristics of Patients with Rheumatoid Arthritis (RA) Starting Triple Therapy and a Combination of a TNF Inhibitor and Methotrexate from a Large US Registry
Joel Kremer^1,2, J. Lynn Palmer³, George W. Reed⁴, Dimitrios A. Pappas⁵, Leslie R Harrold⁶, Jeffrey Greenberg¹ and Jeffrey R. Curtis⁷, ¹Corrona LLC, Waltham, MA, ²Albany Medical College and The Center for Rheumatology, Albany, NY, ³Corrona Research Foundation, Albany, NY, ⁴UMass Medical School, Worcester, MA, ⁵Columbia University, New York, NY, ⁶University of Massachusetts Medical School, Worcester, MA, ⁷University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The combination of methotrexate (MTX), hydroxychloroquine (HCQ) and sulfasalazine (SSZ) has been called Triple Therapy (Triple) and has been compared with a combination of…
Abstract Number: 570 • 2018 ACR/ARHP Annual Meeting
Evaluation of CXCL13, sICAM1, MMP-3 and S100A8/A9 As Serum Biomarkers in Patients with Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab
D. James Haddon, Thierry Sornasse, Michael J. Townsend, Jinglan Pei and Margaret Michalska, Genentech, Inc., South San Francisco, CA
Background/Purpose: Serum levels of C-X-C motif chemokine ligand 13 (CXCL13) and soluble intercellular adhesion molecule-1 (sICAM-1) have been associated with outcomes in patients with rheumatoid…
Abstract Number: 571 • 2018 ACR/ARHP Annual Meeting
United States Rheumatology Practice-Based Real-World Evidence of Methotrexate Utilization and Response to Therapy in Rheumatoid Arthritis Patients Treated with Intravenous Golimumab
Aaron Broadwell¹, Vance Bray², Douglas Conaway³, Joy Schechtman⁴, Alan J. Kivitz⁵, Dennis Parenti⁶, Shawn Black⁶, Stephen Xu⁷, Wayne Langholff⁷ and Shelly Kafka⁶, ¹Rheumatology Osteoporosis Specialists, Shreveport, LA, ²Denver Arthritis Clinic, Denver, CO, ³Carolina Health Specialists, Myrtle Beach, SC, ⁴Sun Valley Arthritis Center, Peoria, AZ, ⁵Altoona Arthritis & Osteoporosis Center, Altoona, PA, ⁶Janssen Scientific Affairs, LLC, Horsham, PA, ⁷Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: AWARE (Comparative and Pragmatic Study of Golimumab IV Versus Infliximab in Rheumatoid Arthritis) is an ongoing Phase 4 comparator study designed to provide a…
Abstract Number: 572 • 2018 ACR/ARHP Annual Meeting
Combining Tocilizumab with Methotrexate Improves Sustainability. Real World Evidence Report from Quebec Database Rhumadata®
Denis Choquette¹, Louis Bessette², Jacques Brown², Boulos Haraoui¹, Frédéric Massicotte¹, Jean-Pierre Pelletier¹, Jean-Pierre Raynauld¹, Marie-Anaïs Rémillard¹, Diane Sauvageau¹, Angèle Turcotte², Édith Villeneuve¹ and Louis Coupal¹, ¹Rheumatology, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montréal, QC, Canada, ²Rheumatology, Centre de l'Ostéoporose et de Rhumatologie de Québec (CORQ), Québec, QC, Canada
Background/Purpose: Biologic therapy targeting TNF have consistently demonstrated better efficacy and effectiveness when combined with a conventional synthetic DMARD (csDMARD), most frequently methotrexate. Although pre-clinical…
Abstract Number: 573 • 2018 ACR/ARHP Annual Meeting
Subcutaneous Tocilizumab in Monotherapy or in Combination with DMARD in Patients with Moderate to Severe Active Rheumatoid Arthritis: Observational Study to Describe Real-World Drug Retention Rate at 12 Months, Interim Analysis
Pascal Hilliquin¹, Thomas Barnetche², Guy Baudens³, Ralph Niarra⁴, Isabelle Idier⁵ and Alain Saraux⁶, ¹Rheumatology, Hôpital Sud Francilien, Corbeil-Essonne, France, ²Rheumatology Department, FHU ACRONIM, Bordeaux University Hospital, Bordeaux, France, ³Rheumatology, CHR Valenciennes, Valenciennes, France, ⁴Biostatistics, Keyrus of behalf of Roche SAS, Boulogne-Billancourt, France, ⁵Medical department, Chugai Pharma France, Paris La Defense, France, ⁶Rheumatology, CHU Brest, Brest, France
Background/Purpose: In France, tocilizumab (TCZ) subcutaneous (sc) 1st prescription and yearly renewal are restricted to hospital. Monitoring may be done by both office-based or hospital…
Abstract Number: 574 • 2018 ACR/ARHP Annual Meeting
Longitudinal Efficacy Analysis of Patients with Active Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Dmards: Response Following Rescue from Baricitinib 2mg to 4mg Once-Daily
Roy Fleischmann¹, Mark C. Genovese², Anabela Cardoso³, Luna Sun³, Yun-Fei Chen³, Chad D. Walls³, Douglas E. Schlichting³, Tsutomu Takeuchi⁴, Maxime Dougados⁵, Josef S. Smolen⁶ and Jeffrey R. Curtis⁷, ¹Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, TX, ²Stanford University Medical Center, Palo Alto, CA, ³Eli Lilly and Company, Indianapolis, IN, ⁴Keio University School of Medicine, Tokyo, Japan, ⁵Paris Descartes University, Hôpital Cochin, Paris, France, ⁶Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ⁷University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Baricitinib (bari), an oral selective Janus kinase 1/2 inhibitor, has shown clinical efficacy in patients (pts) with RA and an inadequate response to conventional…
Abstract Number: 575 • 2018 ACR/ARHP Annual Meeting
Time to Discontinuation of Biologic Therapy By Mechanism of Action in Rheumatoid Arthritis: Results from a Rheumatoid Arthritis Cohort
Mohammad Movahedi¹, Elliot Hepworth², Reza Mirza², Angela Cesta³, Maggie Larche⁴ and Claire Bombardier^1,5,6, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²Department of Internal Medicine, McMaster University, Hamilton, ON, Canada, ³Ontario Best Practices Research Initiative, University Health Network, Toronto, ON, Canada, ⁴Medicine, McMaster University, Hamilton, ON, Canada, ⁵University of Toronto, Department of Medicine (DOM) and Institute of Health Policy Management, and Evaluation (IHPME), Toronto, ON, Canada, ⁶Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Patients with rheumatoid arthritis (RA) may discontinue their biologic disease modifying antirheumatic drug (bDMARDs) due to non-response, loss of response or adverse events. However,…
Abstract Number: 576 • 2018 ACR/ARHP Annual Meeting
An Analysis of Early Introduction of Adalimumab and Subsequent Bio-Free Condition in the Patients with Rheumatoid Arthritis
Satoshi Ito¹, Yoichi Kurossawa^1,2, Eriko Hasegawa^1,2, Daisuke Kobayashi^1,2, Shinji Taniguhi¹, Asami Abe¹, Hiroshi Otani¹, Kiyoshi Nakazono¹, Akira Murasawa¹, Ichiei Narita² and Hajime Ishikawa¹, ¹Department of Rheumatology, Niigata Rheumatic Center, Shibata, Japan, ²Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
Background/Purpose: HOPEFUL-1 trial showed efficacy of combination therapy with adalimumab (ADA) plus methotrexate (MTX) in MTX naïve patients with active early rheumatoid arthritis (eRA). In…
Abstract Number: 577 • 2018 ACR/ARHP Annual Meeting
Expanded Autoantibody Profiles Predict Treatment Response to Biologic Therapy in Rheumatoid Arthritis
Ted R. Mikuls¹, Amrita Bath², Bryant R. England³, Michael J. Duryee⁴, Carlos D. Hunter⁴, Joel Kremer⁵, Dimitrios A. Pappas^6,7, William H. Robinson⁸, Jeffrey R. Curtis⁹ and Geoffrey M. Thiele¹⁰, ¹Internal Medicine, Division of Rheumatology, VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ²Rheumatology, University of Nebraska Medical Center, Omaha, NE, ³Rheumatology, VA Nebraska-Western Iowa Health Care System & University of Nebraska Medical Center, Omaha, NE, ⁴Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁵Albany Medical Center, Albany, NY, ⁶Columbia University, New York, NY, ⁷Corrona, LLC, Waltham, MA, ⁸Stanford University, Palo Alto, CA, ⁹University of Alabama at Birmingham, Birmingham, AL, ¹⁰University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Although biologics represent a major advance in rheumatoid arthritis (RA), many patients fail to achieve adequate responses to these agents. As previous studies have…
Abstract Number: 578 • 2018 ACR/ARHP Annual Meeting
Effect of Disease Duration and Other Patient Baseline Characteristics on Outcomes in Tocilizumab-Treated Rheumatoid Arthritis Patients: A Pooled Analysis
Andrea Rubbert-Roth¹, Daniel Aletaha², Jenny Devenport³, Paris N. Sidiropoulos³, Yves Luder⁴, Michael Edwardes⁵ and Johannes W. G. Jacobs⁶, ¹Kantonsspital St Gallen, St Gallen, Switzerland, ²Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, Vienna, Austria, ³Genentech, Inc., South San Francisco, CA, ⁴F. Hoffmann-La Roche, Basel, Switzerland, ⁵Everest Clinical Research, Markham, ON, Canada, ⁶Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, the Netherlands, Utrecht, Netherlands
Background/Purpose: Tocilizumab (TCZ) efficacy and safety in rheumatoid arthritis (RA) have been well established by numerous phase 3 and 4 studies and observational studies. The…
Abstract Number: 579 • 2018 ACR/ARHP Annual Meeting
Changes in DNA Methylation Identify Response to Treatment with Methotrexate and TNF Inhibitors Among RA Patients
Cameron Adams¹, Katie Marker¹, Melissa Krueger², Lisa Barcellos¹ and Lindsey A. Criswell³, ¹School of Public Health, UC Berkeley, Berkeley, CA, ²UC San Francisco, San Francisco,, CA, ³University of California San Francisco, San Francisco, CA
Background/Purpose: Epigenetic modifications including DNA methylation are implicated in the development and progression of autoimmune diseases, such as rheumatoid arthritis [MIM 180300]. Evidence indicates that…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].